TITLE

Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting

AUTHOR(S)
PICCINNI, CARLO; MOTOLA, DOMENICO; MARCHESINI, GIULIO; POLUZZI, ELISABETTA
PUB. DATE
June 2011
SOURCE
Diabetes Care;Jun2011, Vol. 34 Issue 6, p1369
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE--To analyze the association between pioglitazone use and bladder cancer through a spontaneous adverse event reporting system for medications. RESEARCH DESIGN AND METHODS--Case/noncase bladder cancer reports associated with antidiabetic drug use were retrieved from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) between 2004 and 2009 and analyzed by the reporting odds ratio (ROR). RESULTS--Ninety-three reports of bladder cancer were retrieved, corresponding to 138 drug-reaction pairs (pioglitazone, 31; insulin, 29; metformin, 25; glimepiride, 13; exenatide, 8; others, 22). ROR was indicative of a definite risk for pioglitazone (4.30 [95% CI 2.82-6.52]), and a much weaker risk for gliclazide and acarbose, with very few cases being treated with these two drugs (6 and 4, respectively). CONCLUSIONS--In agreement with preclinical and clinical studies, AERS analysis is consistent with an association between pioglitazone and bladder cancer. This issue needs constant epidemiologic surveillance and urgent definition by more specific studies.
ACCESSION #
65099006

 

Related Articles

  • Definite signal for bladder cancer associated with pioglitazone.  // Reactions Weekly;5/28/2011, Issue 1353, p4 

    The article reports on the findings of an analysis of data from the U.S. Food and Drug Administration's (FDA) adverse events reporting system (AERS) which confirmed the association between pioglitazone use and bladder cancer. Researchers from the University of Bologna in Italy analyzed 86,987...

  • Diabetes Drug May Be Associated With Increase in Risk of Bladder Cancer. Stephenson, Joan // JAMA: Journal of the American Medical Association;7/13/2011, Vol. 306 Issue 2, p143 

    The article discusses a warning issued by the U.S. Food and Drug Administration (FDA) that the use of the diabetic agent pioglitazone for over a year may be linked to an increased risk of bladder cancer.

  • Actos and bladder cancer risk. Elliott, William T. // Neurology Alert;Aug2011 Pharmacology Watch, p2 

    The article reports that the U.S. Food and Drug Administration (FDA) has issued a warning against possible bladder cancer risk associated with the use of the diabetes drug pioglitazone (Actos).

  • FDA announces preliminary safety review of pioglitazone.  // Hem/Onc Today;10/10/2010, Vol. 11 Issue 19, p6 

    This article reports on the review being conducted by the U.S. Food and Drug Administration of preliminary results from a study suggesting a link between pioglitazone and an increased risk for bladder cancer.

  • Actos and bladder cancer risk.  // Internal Medicine Alert;7/15/2011 Pharmacology Watch, p2 

    The article reports on the warning issued by the U.S. Food and Drug Administration (FDA) concerning the potential risk of bladder cancer associated with the use of the diabetes drug pioglitazone (Actos).

  • FDA issues pioglitazone warning based on 5-year study results.  // Reactions Weekly;6/25/2011, Issue 1357, p2 

    The article focuses on a study suggesting that the risk of bladder cancer increases with increasing dose and duration of pioglitazone use, which has been released by the U.S. Food and Drug Administration (FDA) as of June 2011.

  • France, Germany suspend pioglitazone.  // Reactions Weekly;6/18/2011, Issue 1356, p2 

    The article reports on the decision of the French Medicines Agency to suspend the use of pioglitazone-containing medicines in response to a retrospective cohort study which revealed an increased risk of bladder cancer in patients receiving pioglitazone.

  • Avandia, Risk of Congestive Heart Failure Significant Safety Risk.  // Neurology Alert;Jul2007, Vol. 25 Issue 11, p1 

    The article reports on the plan of the U.S. Food and Drug Administration (FDA) to issue a black box warning to the rosiglitazone drug Avandia and the pioglitazone drug Actos manufactured by GlaxoSmithKline due to concerns over health failure associated with the use of the drugs. The...

  • Amylin Shares Jump on NDA but Drug Class Concerns Linger. Hollingsworth, Catherine // BioWorld Today;5/6/2009, Vol. 20 Issue 86, p1 

    The article reports that the shares of Amylin slightly increased after the company filed for regulatory approval for its exenatide drug for diabetes at the U.S. Food and Drug Administration (FDA). Shares of Amylin's partners Alkermes and Eli Lilly and Co. also increased after the filing....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics